| Interferon-alpha in the treatment of essential thrombocythemia. | |
| | |
MedLine Citation:
|
PMID: 8951784 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Interferon alpha (IFN) inhibits the growth of megakaryocytic progenitors in normal hematopoiesis and in patients with essential thrombocythemia (ET) leading to a reduction of peripheral platelet counts. The effectiveness in the induction therapy of patients with ET is demonstrated in 11 international studies including 212 patients. With an average dose of about 3 mill IU IFN daily, the response rate was about 90%. Further studies investigated the practicability and the success of IFN maintenance therapy. The results show that IFN can effectively control platelet counts over a period of several years. During maintenance the IFN dose could be reduced in the majority of patients. However, sustained unmaintained complete remissions were obtained in only 12% of the patients. Side effects were frequently the limiting factors in treatment with IFN especially in older patients. Analyzing a total of 273 patients, IFN therapy was terminated in 25% against the primary treatment plan. Of the currently effective drugs in controlling the platelet counts in ET, IFN is the only antiproliferative agent with immuno-modulating properties. Thus far, no leukemogenic or significant gonadotoxic effects have been observed. In a subset of the patients off all therapy, the sustained remissions support a long-term tumor load reduction effect by IFN. Thus, IFN is a promising agent in cytoreductive treatment of ET especially in younger patients. |
| | |
Authors:
|
E Lengfelder; M Griesshammer; R Hehlmann |
Related Documents
:
|
7786774 - Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: re... 9753054 - The expression of co-stimulatory molecules and their relationship to the prognosis of h... 12542484 - Early detection of meningeal localization in acute promyelocytic leukaemia patients wit... 6531754 - High fibrinopeptide a (fpa) levels in acute non-lymphocytic leukemia are reduced by hep... 8321904 - Transesophageal echocardiography as a tool in the evaluation of patients with embolic d... 22210534 - Predictors of worsening renal function after computed tomography coronary angiography: ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 22 Suppl 1 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 1996 Sep |
Date Detail:
|
Created Date: 1997-03-20 Completed Date: 1997-03-20 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 135-42 Citation Subset: IM |
Affiliation:
|
III. Medizinische Klinik Mannheim, University of Heidelberg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Marrow
/
drug effects,
pathology Clinical Trials as Topic Follow-Up Studies Humans Immunologic Factors / adverse effects, pharmacology, therapeutic use* Interferon-alpha / adverse effects, pharmacology, therapeutic use* Megakaryocytes / drug effects, pathology Middle Aged Platelet Aggregation Inhibitors / therapeutic use Platelet Count / drug effects Quinazolines / therapeutic use Remission Induction Thrombocythemia, Essential / therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Immunologic Factors; 0/Interferon-alpha; 0/Platelet Aggregation Inhibitors; 0/Quinazolines; 0/anagrelide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on ...
Next Document: Interferon treatment in polycythaemia vera.